Lung cancer combo therapy trial halted after just one patient
NCT ID NCT04786093
First seen May 08, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study aimed to see if adding a type of immunotherapy (durvalumab) to two different schedules of precise radiation therapy could improve quality of life for people with advanced non-small cell lung cancer. Only one person was enrolled before the study was stopped early. The main goal was to measure changes in quality of life using a standard questionnaire.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.